December 3, 2019 10:54 AM ESTUpdated 11:14 AM
News Briefing

Ab­b­Vie picks first Alzheimer's, Parkin­son's tar­gets in Mis­sion pact; Amarin files for Vas­cepa OK in Eu­rope

Kathy Wong

Editor

→ Back in 2018, Ab­b­Vie teamed up with pro­tein degra­da­tion ex­perts at Mis­sion Ther­a­peu­tics to fo­cus on deu­biq­ui­ty­lat­ing en­zymes, or DUBs, to tack­le Alzheimer’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times